- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05851391
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest (RESTORE)
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest (RESTORE)
Study Overview
Status
Conditions
Detailed Description
Rationale: Seizures emerge as a complication of hypoxic-ischemic brain injury in near a third of patients successfully resuscitated from cardiac arrest. Seizures post-cardiac arrest can be refractory to treatment with anti-seizure medications and anesthetics may be used for refractory status epilepticus control. Anesthetic treatment guided by continuous EEG can target burst suppression or seizure suppression, however it is not known which strategy is superior for achieving PCARSE control.
Objective: determine the safety and feasibility of post-cardiac arrest refractory status epilepticus (PCARSE) treatment using EEG goals for intravenous anesthetic titration (burst suppression vs. seizure suppression).
Clinical Trial Phase: II
Study Design: prospective, randomized, open-label, blinded end-point, concurrently-controlled, parallel arms design clinical trial.
Study Period: two years
Study Population: unconscious cardiac arrest survivors with return of spontaneous circulation who develop post-cardiac arrest refractory status epilepticus (PCARSE).
Interventions: anesthetic use targeting burst suppression vs. seizure suppression on EEG for 24 hours. Intervention maybe repeated using the dame EEG target once in case of PCARSE recurrence.
Sample Size: 30 subjects randomized in a 1:1 ratio to either burst suppression or seizure suppression EEG targets.
Primary Endpoints: Safety and feasibility of seizure control using burst suppression or seizure suppression EEG targets for PCARSE treatment.
Secondary Endpoints: Seizure recurrence incidence, time to seizure recurrence, number and dose of anti-seizure medication and anesthetic needed for PCARSE control, Death or disability according to the Cerebral Performance Category at Discharge (30 days), and Death or disability according to the modified Rankin Scale at Discharge (30 days).
Risks: Participants receiving anesthetics for PCARSE treatment will be monitored for hypotension, propofol infusion syndrome, and hypertriglyceridemia. Patients with PCARSE are at high risk for death and prolonged hospital stays.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Edilberto Amorim, MD
- Phone Number: 628-206-3203
- Email: restorestudy@ucsf.edu
Study Contact Backup
- Name: Dominica Randazzo
- Phone Number: (415)514-2120
- Email: restorestudy@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Recruiting
- Zuckerberg San Francisco General Hospital
-
Contact:
- Edilberto Amorim, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years old
- Non-traumatic, out-of-hospital cardiac arrest
- Comatose on admission - defined as not following commands
- Return of spontaneous circulation (ROSC) within less than 45 minutes
- Admission to the intensive care unit
- Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous
EEG monitoring within 7 days from ROSC
Exclusion Criteria:
- Acute cerebral hemorrhage or infarction
- Pregnancy
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Burst Suppression EEG Target
Anesthetic will be titrated to achieve burst suppression on continuous EEG (50-99% attenuation/suppression) for 24 hours.
|
The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (>50% suppressed/attenuated).
After this 24-hour period, this target would be continued for 24 hours.
The anesthetic will then be tapered under EEG monitoring.
In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
|
Other: Seizure Suppression EEG Target
Anesthetic will be titrated to achieve seizure suppression on continuous EEG for 24 hours.
|
is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background.
This target would be continued for 24 hours.
After this 24-hours period, this target would be continued for 24 hours.
The anesthetic will then be tapered under EEG monitoring.
In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-cardiac arrest refractory status epilepticus control
Time Frame: 48 hours
|
Continuous EEG will be monitored to determine time to PCARSE recurrence during the anesthetic maintenance and anesthetic weaning phase (combined)
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seizure recurrence incidence and duration (burden)
Time Frame: 24-48 hours
|
Presence of seizures on EEG after initiation of anesthetic maintenance phase
|
24-48 hours
|
Neurological Function at Discharge (CPC: Cerebral Performance Category)
Time Frame: 30 days
|
Cerebral Performance Category score at Discharge
|
30 days
|
Neurological Function at Discharge (mRS: modified Ranking Scale)
Time Frame: 30 days
|
modified Rankin Scale score at Discharge
|
30 days
|
Neurological Function 90 days (CPC: Cerebral Performance Category)
Time Frame: 90 days
|
Cerebral Performance Category score at 90 days
|
90 days
|
Neurological Function 90 days (mRS: modified Ranking Scale)
Time Frame: 90 days
|
modified Rankin Scale score at Discharge
|
90 days
|
Neurological Function 180 days (mRS: modified Ranking Scale)
Time Frame: 180 days
|
modified Rankin Scale score at Discharge
|
180 days
|
Neurological Function180 days (mRS: modified Ranking Scale)
Time Frame: 180 days
|
modified Rankin Scale score at Discharge
|
180 days
|
PCARSE Treatment Intensity
Time Frame: 24-48 hours
|
Number of anti-seizure medications and anesthetics used for PCARSE control after initiation of anesthetic maintenance phase and prior to weaning
|
24-48 hours
|
Seizure recurrence incidence and duration (burden)
Time Frame: 24-48 hours
|
Presence of seizures on EEG after initiation of anesthetic weaning phase
|
24-48 hours
|
PCARSE Treatment Intensity
Time Frame: 24-48 hours
|
Dose of anti-seizure medications and anesthetics used for PCARSE control after initiation of anesthetic maintenance phase and prior to weaning
|
24-48 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Edilberto Amorim, MD, Assistant Professor of Neurology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Signs and Symptoms, Respiratory
- Hypoxia, Brain
- Brain Ischemia
- Ischemia
- Seizures
- Brain Diseases
- Heart Arrest
- Hypoxia
- Hypoxia-Ischemia, Brain
- Status Epilepticus
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics
Other Study ID Numbers
- 21-34336
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seizures
-
Eisai Inc.CompletedPartial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized SeizuresUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedGeneralized Tonic Clonic SeizuresKorea, Republic of, United States, Austria, Serbia, India, Spain, Poland, Malaysia, China, Bulgaria, Denmark, Greece, Hungary, United Kingdom, Belarus, France, Montenegro, Philippines, Romania, Russian Federation, Slovakia, Ukraine, Lebano... and more
-
Lundbeck LLCCompletedAdult Refractory Complex Partial SeizuresUnited States
-
University Hospital, BordeauxCompletedPsychogenic Nonepileptic Seizures (PNESs)France
-
Xenon Pharmaceuticals Inc.Worldwide Clinical TrialsRecruitingPrimary Generalized Tonic-Clonic SeizuresUnited States, Australia, Bulgaria, Poland, Czechia, Canada, Portugal, Croatia, Italy, Spain
-
UCB Biopharma SRLRecruitingStereotypical Prolonged SeizuresUnited States, Bulgaria, China, Czechia, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, France, Australia
-
UCB Biopharma SRLEnrolling by invitationStereotypical Prolonged SeizuresUnited States, Bulgaria, China, Czechia, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, Australia
-
Central Hospital, Nancy, FranceCompletedPsychogenic Non-epileptic SeizuresFrance
-
ValexfarmCompletedEpilepsy | Complex Partial Seizures | Simple Partial Seizures | Partial Seizures With Secondary GeneralizationRussian Federation
-
University of Alabama at BirminghamBaylor College of Medicine; Yale UniversityRecruitingConvulsion, Non-Epileptic | Functional SeizuresUnited States
Clinical Trials on Burst Suppression EEG Target Intravenous Anesthesia
-
Technical University of MunichActive, not recruitingGeneral Anesthesia | Electroencephalogram | Burst SuppressionGermany
-
Duzce UniversityCompletedCardiac Event | Anesthesia,GeneralTurkey
-
Centre Cardiologique du NordNot yet recruitingPost-operative Delirium | Anaesthetic DepthFrance
-
Mayo ClinicRecruiting
-
Universidad del DesarrolloCompleted
-
Ospedale San RaffaeleCompletedGastrointestinal Endoscopy | Propofol | Target Controlled Infusion | Moderate SedationItaly
-
Pusan National University HospitalCompletedPremedication | Anxiety Preoperative | Midazolam PremedicationKorea, Republic of
-
Boston Medical CenterCompleted
-
Mahidol UniversityCompletedSpine DiseasesThailand
-
Scarlata, Simone, M.D.CompletedLung Cancer | Endoscopy | Sedation Complication | Lung; NodeItaly